New AI-Guided Ultrasound System Enabling Rapid Assessments of DVTs Introduced

Having achieved CE Mark for sales in Europe and the UK, ThinkSono is now collaborating with Clarius on clinical studies in the United States to prepare for FDA submission

Summation

  • ThinkSono purchased their first Clarius scanner in 2017 and were the first partner to use the Clarius Cast API, developed for researchers and AI companies to help bring technologies to market more quickly by leveraging easy access to real-time ultrasound data to train AI algorithms and deploy AI solutions.
  • Further clinical studies are currently underway in the United States at NYU Longone Health and Temple Health, these are based on the successful multi-site clinical trials held in Europe last year, which were used to obtain the Class IIb CE mark for the ThinkSono Guidance System.
  • Clarius Mobile Health, a leading provider of high-definition handheld ultrasound systems, and ThinkSono, a pioneering medical technology company specializing in ultrasound artificial intelligence (AI) guidance solutions, are introducing a new AI-guided ultrasound system in Europe, which will improve the efficiency of detecting deep vein thrombosis (DVT).

AI-Guded Ultrasound System

Clarius Mobile Health, a leading provider of high-definition handheld ultrasound systems, and ThinkSono, a pioneering medical technology company specializing in ultrasound artificial intelligence (AI) guidance solutions, are introducing a new AI-guided ultrasound system in Europe, which will improve the efficiency of detecting deep vein thrombosis (DVT). ThinkSono Guidance, an AI App that pairs with Clarius ultrasound scanners, recently attained Class llb CE mark regulatory approval.

DVT

DVT is a blood clot found commonly in the leg and is a leading cause of preventable hospital death in Europe and the United States. Patients often wait for hours or days for test results performed by ultrasound-trained clinicians. ThinkSono Guidance enables non-ultrasound trained healthcare professionals to use the Clarius handheld ultrasound scanner to collect DVT exam data for a qualified clinician to review. This can speed up the diagnosis from several hours to as little as 15 minutes.

Fouad-Al Noor, CEO and Co-founder of ThinkSono

“Clarius has been an invaluable partner in helping us bring ThinkSono Guidance to market quickly to help non-ultrasound trained staff such as nurses improve the DVT pathway by scanning for DVTs at the bedside. Our App integrates seamlessly with Clarius scanners through the research SDK, which sends streams of real-time data to the ThinkSono App that in turn providing instant guidance to users as they perform an ultrasound exam. Our partnership with Clarius has been vital in running our clinical studies.”

Further clinical studies are currently underway in the United States at NYU Longone Health and Temple Health, these are based on the successful multi-site clinical trials held in Europe last year, which were used to obtain the Class IIb CE mark for the ThinkSono Guidance System.

ThinkSono purchased their first Clarius scanner in 2017 and were the first partner to use the Clarius Cast API, developed for researchers and AI companies to help bring technologies to market more quickly by leveraging easy access to real-time ultrasound data to train AI algorithms and deploy AI solutions. ThinkSono now uses Clarius’ Solum software development kit (SDK), enabling the company to create a bespoke solution tailored to their DVT application. ThinkSono will be marketing and selling the complete DVT solution including a Clarius ultrasound scanner directly starting in the UK, Germany and Greece.

Kris Dickie, Chief Technology Officer at Clarius

“Working closely with ThinkSono since the inception of their company, when they utilized our first-generation high-performance scanners, has been a delight. Seeing unique AI tools like theirs being developed for commercial use on our platform truly validates the technology beyond the already broad clinical segments that Clarius currently serves.”

Third-party Developers

The Clarius SDK suite empowers third-party developers to seamlessly integrate AI-powered ultrasound software with Clarius handheld ultrasound systems, the Clarius App, and the Clarius Cloud exam management platform. It provides a set of tools enabling developers to quickly take their solution from code directly to the clinician’s hand without creating custom hardware.

More News

Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled Substance

"We are thrilled with the DEA's decision, which underscores the potential of MIRA-55 as a groundbreaking therapeutic candidate," said Erez Aminov, Chairman & CEO of MIRA Pharmaceuticals. "This ruling allows us to focus on MIRA-55's unique cognitive and anxiety benefits. With access to $90B traditional neurological and $30B cannabis markets, MIRA-55 represents a significant value proposition for our company.  We remain committed to advancing it through the development pipeline for treating these diseases from which so many currently suffer."

Abu Dhabi Issues First BioTech Inventor-Class Golden Visa to Catalyze “Made-In-Abu-Dhabi IP” to Rockefeller University Inventor Dr Kambiz Shekdar, PhD

Dr Kambiz Shekdar said: "I gratefully take this opportunity as my solemn commitment to help build up the BioTech sector in Abu Dhabi with the same home-grown can-do-and-have-done record of accomplishment demonstrated by Emirati leadership, its people, and nation, and to do so collegially with the best of the best of the world's human capital across frontier technologies who, like myself, are drawn to the UAE with the thirst to pioneer and build better like only possible in the red-hot entrepreneurial climate of the UAE."

Activation Capital Introduces ‘Frontier BioHealth’ to Catalyze Life Science Startups

"We celebrate the growing base of research and technological advances within the region's health and life sciences sector," said Chandra Briggman, President and CEO of Activation Capital.

By using this website you agree to accept Medical Device News Magazine Privacy Policy